This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

Delivery is still biggest area of need in peptide, oligonucleotide and mRNA therapeutics

Share this article

Delivery and targeting are still seen as the biggest areas of need for oligonucleotide, peptide, mRNA and gene edited therapeutics, according to our industry report.

The report collates interesting data and insights from our recent global survey of professionals working across genome editing and oligonucleotide, peptide and mRNA therapeutics.

Explore the full Oligonucleotide, Peptide, mRNA and Genome Edited Therapeutics State of the Industry Report 2021 here.

The rise of mRNA therapeutics

Delivery and targeting had previously been found as top areas of need in our industry report in 2019. However, scale of manufacturing has since become the third biggest area of demand, a higher priority than it was in 2019. This is followed by mRNA and siRNA, as RNA therapeutics have seen a boom in interest and demand since the beginning of the COVID-19 pandemic.

Delivery and targeting are still the greatest areas of need for advancement in peptide, oligonucleotide and mRNA therapeutics

The most common delivery systems

The survey found that naked systems with lipophilic conjugates are now the most common form of local delivery for macromolecular drugs, used by 46% of the industry professionals. Meanwhile, systems formulated in LNPs were found to be the most common method for systemic macromolecular drug delivery.

The biggest future advancements

The survey participants were also asked what major advancements each technology field will see in the next 5 years. Effective delivery was again the top-suggested major advancement for oligonucleotides over the next 5 years, as it was in our 2019 survey. Similarly, in relation to genome editing, the most common suggestion was a more mature clinical pipeline, the same top answer found relating to CRISPR therapeutics in 2019.

As the next biggest advancement for peptides, the most common prediction was oral delivery systems and, perhaps not surprisingly, further uses in vaccines was the most predicted major advancement for mRNA therapeutics.

Explore the full Oligonucleotide, Peptide, mRNA and Genome Edited Therapeutics State of the Industry Report 2021 here.

Share this article

Upcoming event

TIDES Asia: Oligonucleotide & Peptide Therapeutics Virtual Scientific Forum

02 - 05 Mar 2021
Industry leaders and service providers share cutting-edge content and company expertise across the Oligonucleotide, Peptide, mRNA and Drug Delivery spectrum
Go to site